We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current VM market cap is 13.93M. The company's latest EPS is CAD -0.0105 and P/E is -9.52.
| Year End November 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 0 | 0 | 0 | 4k | 0 |
| Operating Income | -415k | -907k | -1.73M | -1.35M | -1.05M |
| Net Income | -552k | -1.14M | -2.05M | -1.75M | -1.4M |
| Year End November 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 1.61M | 1.28M | 2.57M | 2.1M | 2.16M |
| Total Liabilities | 852k | 969k | 660k | 631k | 728k |
| Total Equity | 754k | 306k | 1.91M | 1.46M | 1.44M |
| Year End November 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | -637k | -272k | -1.65M | -1.72M | -991k |
| Investing | -170k | -152k | -432k | -274k | -175k |
| Financing | 736k | 351k | 2.9M | 1.21M | 1.14M |
| Market Cap | 13.93M |
| Price to Earnings Ratio | -9.52 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 9.24 |
| Dividend Yield | - |
| Shares Outstanding | 132.7M |
| Average Volume (1 week) | 393.46k |
| Average Volume (1 Month) | 159.18k |
| 52 Week Change | 110.00% |
| 52 Week High | 0.105 |
| 52 Week Low | 0.04 |
| Spread (Intraday) | 0.01 (9.52%) |
| Company Name | Voyageur Pharmaceuticals Ltd |
| Address |
suite 800, 333 7th avenue sw calgary, alberta T2P 2Z1 |
| Website | https://www.voyageurpharmaceuticals.ca |
| Industry | unit inv tr, closed-end mgmt (6726) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
